|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 8/18 protects breast cancer cell lines from TRAIL-induced apoptosis.
|
29796187 |
2018 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Serial whole tissue sections of 154 consecutive invasive breast carcinomas were stained for Ki67 and cytokeratin 8/18 with immunohistochemistry in a clinical setting.
|
29349710 |
2018 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Two different methods were used to label breast cancer tissues for BRCA1: (1) Dual immunofluoresent staining with BRCA1 and cytokeratin 8/18 and (2) immunohistochemical staining using the previously validated MS110 mouse monoclonal antibody.
|
28863181 |
2017 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Identification of a mimotope for circulating anti-cytokeratin 8/18 antibody and its usage for the diagnosis of breast cancer.
|
23128437 |
2013 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of SMAR1 and Cytokeratin 8 proteins in different grades of cancer using tissue microarray point out at the inverse expression profiles of these genes (i.e. low levels of SMAR1 correlating with high expression of Cytokeratin 8) in higher grades of breast cancer.
|
18822384 |
2009 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
In this report, we observed elevated expression of cytokeratin 8 (CK8) in MCF-7/MX, a mitoxantrone (MX)-selected human breast tumor cell line with the MDR phenotype known as overexpression of breast cancer resistant protein (BCRP).
|
18725232 |
2008 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
A human breast cancer cell line (MCF7S) and its multidrug resistant (MDR) subline (MCF7R) were characterized here for their intermediate filaments (IFs) expression (cytokeratin 8, 18, 19 and vimentin) as a function of their resistance phenotype.
|
9413178 |
1998 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines.
|
7542667 |
1995 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Dual-immunostaining for mast cell tryptase and epithelial cytokeratin-8 and whole slide image analysis were used to assess total mast cell number, mast cell density (mast cell number/tissue area), and mast cell number per epithelial or stromal area in TMA spots containing tumor (up to 4 per man).
|
27868214 |
2017 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The complexity index was measured using images of tumor samples (n=64) stained for cytokeratin‑8.
|
25502877 |
2015 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the expression of CK8 is clearly dependent on the degree of histological tumor cell differentiation.
|
26124342 |
2015 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Therefore, the results presented here highlight the mechanism of Cytokeratin 8 gene regulation by interplay of tumor suppressor proteins SMAR1 and p53.
|
18822384 |
2009 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Therefore, CK8 in sera may become a novel tumor marker in patients with lung cancer.
|
12367790 |
2002 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Only cytokeratin 19 showed significant correlation with increasing tumor size (P = 0.006). mRNA expression for cytokeratin 8 was significantly higher in node-positive compared with node-negative disease (P = 0.02).
|
9701399 |
1998 |
|
Neoplasms
|
0.070 |
PosttranslationalModification
|
group |
BEFREE |
p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
|
8615594 |
1996 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 8/18 protects breast cancer cell lines from TRAIL-induced apoptosis.
|
29796187 |
2018 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
Two different methods were used to label breast cancer tissues for BRCA1: (1) Dual immunofluoresent staining with BRCA1 and cytokeratin 8/18 and (2) immunohistochemical staining using the previously validated MS110 mouse monoclonal antibody.
|
28863181 |
2017 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
Identification of a mimotope for circulating anti-cytokeratin 8/18 antibody and its usage for the diagnosis of breast cancer.
|
23128437 |
2013 |
|
Malignant neoplasm of breast
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of SMAR1 and Cytokeratin 8 proteins in different grades of cancer using tissue microarray point out at the inverse expression profiles of these genes (i.e. low levels of SMAR1 correlating with high expression of Cytokeratin 8) in higher grades of breast cancer.
|
18822384 |
2009 |
|
Malignant neoplasm of breast
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In this report, we observed elevated expression of cytokeratin 8 (CK8) in MCF-7/MX, a mitoxantrone (MX)-selected human breast tumor cell line with the MDR phenotype known as overexpression of breast cancer resistant protein (BCRP).
|
18725232 |
2008 |
|
Malignant neoplasm of breast
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
A human breast cancer cell line (MCF7S) and its multidrug resistant (MDR) subline (MCF7R) were characterized here for their intermediate filaments (IFs) expression (cytokeratin 8, 18, 19 and vimentin) as a function of their resistance phenotype.
|
9413178 |
1998 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
It also decreased the expression of pro-inflammatory cytokines, such as IL-13 and CD30L, in IBD and CAC model mice possibly by inhibiting Toll-like receptor 4 (TLR4)/NF-κB signalling and the expression of colon cancer markers, such as carcinoembryonic antigen, cytokeratin 8, CK18 and p53, in CAC model mice.
|
30472806 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
It also decreased the expression of pro-inflammatory cytokines, such as IL-13 and CD30L, in IBD and CAC model mice possibly by inhibiting Toll-like receptor 4 (TLR4)/NF-κB signalling and the expression of colon cancer markers, such as carcinoembryonic antigen, cytokeratin 8, CK18 and p53, in CAC model mice.
|
30472806 |
2019 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The mechanism of its antitumor effect involved in (a) reducing oxidative stress injury through up-regulating activities of CAT and SOD; (b) down-regulating the levels of inflammatory factors, like TNF-α, IL6, COX-2, and PGE2; (c) activation of caspase-3 and up-regulating the pro-apoptotic protein Bax; (d) decreasing the expression of PCNA; (e) depressing the expression of cancer stem cells marker CD133; (f) suppressing aberrant expression of cytokeratin 8 and 18; and (g) inhibiting EGFR/ PI3 K/Akt, EGFR/Ras/Erk and NF-κB pathways.
|
27991692 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The mechanism of its antitumor effect involved in (a) reducing oxidative stress injury through up-regulating activities of CAT and SOD; (b) down-regulating the levels of inflammatory factors, like TNF-α, IL6, COX-2, and PGE2; (c) activation of caspase-3 and up-regulating the pro-apoptotic protein Bax; (d) decreasing the expression of PCNA; (e) depressing the expression of cancer stem cells marker CD133; (f) suppressing aberrant expression of cytokeratin 8 and 18; and (g) inhibiting EGFR/ PI3 K/Akt, EGFR/Ras/Erk and NF-κB pathways.
|
27991692 |
2017 |